Skip to content

Noninvasive brain stimulation improves cognitive function in Alzheimer's Disease: a pilot clinical study

Effect of noninvasive brain stimulation for improving cognitive function in Alzheimer's Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009227
Enrollment
Unknown
Registered
2016-09-20
Start date
2016-09-19
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Group 1:Routine treatment + rTMS on middle lobes and frontal lobes
Group 2:Routine treatment + tDCS on middle lobes and frontal lobes
Group 3:Routine treatment + rTMS on frontal lobes and tDCS on middle lobes
Group 4:Routine treatment + rTMS on frontal lobes

Sponsors

Department of Rehabilitation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed as mild-to-moderate AD (according to the criteria of NINCDS-ADRDA, with MMSEscores=15, CDR scores=0.5-2) were enrolled in this study. All patients took medicine (such as donepezil) for more than 3 months before the recruitment. Patients aged more than 55 and the course of disease is more than 6 months. Insidious onset and symptoms gradually appear in a few months to several years, rather than suddenly happen within a few hours or days with early, significant episodic memory disorders. All patients sign informed consent.

Exclusion criteria

Exclusion criteria: (1) other diseases cause of dementia, such as vascular dementia and frontotemporal dementia (FTD), DLB, folic acid or vitamin B12 deficiency, syphilitic dementia, thyroid function is low, etc; (2) depression (HAMD scores=17) caused by the pseudo dementia patients; (3) other nervous system diseases, systemic diseases and poisoning caused by dementia patients; (4) has a history of mental illness, such as schizophrenia and affective disorder; (5) out of delirium, epilepsy; (6) has a history of alcoholism or psychiatric drug abuse; (7) Patients heart, blood vessels, lung, liver, kidney and other major body in the acute phase of disease; (8) stimulate locations with metal; (9) hearing and eyesight severe with abnormalities; (10) Pet-name ruby skull damage or loss, can't cooperate with treatment.Rule out diabetes, heart disease, cerebrovascular disease, obesity, cancer.

Design outcomes

Primary

MeasureTime frame
Neuropsychological assessment;

Secondary

MeasureTime frame
imaging assessment;

Countries

China

Contacts

Public ContactXiaolin Huang

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

xiaolinh2006@126.com+86 13871261957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026